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Abstract
Over the past decade, numerous minimally invasive thermal procedures have been
investigated to treat benign prostate hyperplasia and prostate cancer. These
hyperthermia and thermal surgery techniques have employed RF energy, microwave
radiation, laser, and acoustic energy to heat and necrose a localized region of tissue.
Of these methods, ultrasound has shown considerable promise due to its ability to
produce more precise and deeper foci in vivo. In addition, recent advances in
ultrasound amplifier and fabrication technologies have prompted refined clinical heating
devices. In this study, a linear, transrectal, ultrasound phased array capable of ablating
large tissue volumes was fabricated and evaluated in tissue. The device was designed
to be MRI compatible for use with MRI thermometry and guidance. The intracavitary
applicator increases treatable tissue volume by utilizing an ultrasonic motor to provide
up to a 100-degree mechanical rotation angle to a 62-element 1 D ultrasound array. An
aperiodic array geometry was used to reduce grating lobes. The applicator built under
constraints of the small rectal dimensions also incorporated a 1 mm thin custom-
fabricated Kapton flexible circuit to interconnect the elements of the phased array to the
ultrasound driving system. The Kapton interconnect reduced cable crosstalk and hence
also improved the acoustic efficiency of the array. The array was driven by a multi-
channel ultrasound amplifier system, which incorporates power and phase feedback
circuitry to improve thermal focusing. MRI guided in vivo and ex vivo experiments were
performed to verify the array's large volume ablative capabilities. Ex vivo bovine
experiments were performed to assess the focusing range of applicator. The array
generated foci in a 3 cm (2 to 5 cm from the array surface along the axis normal to the
array) by 5.5 cm (along the long axis of the array) by 6 cm (along the transverse axis of
the array at a depth of 4 cm) volume. Following ex vivo studies, in vivo rabbit thigh
experiments were performed to evaluate the lesion producing capabilities in perfused
tissue. The array generated 3 cm x 2 cm x 2 cm lesions with 8-12 half minute
sonications equally spaced in the volume. The results indicate that transrectal
ultrasound coagulation of the whole prostate is feasible with the method developed.
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1 Introduction
1.1 Prostate Disease
Prostate Disease is among the leading causes of morbidity and mortality in
the United States. In 1999, there will be an estimated 179,300 new cases of
prostate cancer, making it the most frequently diagnosed cancer in the
population (Landis et al. 1999). This year, 37,000 men will die from prostate
carcinoma, second only to lung cancer in neoplasia related fatalities. While
prostate cancer is a leading of cause mortality in the United States, benign
prostatic hyperplasia (BPH) or prostatism is one of the leading causes of
morbidity. Pathologically, BPH involves benign nodular hyperplasia of both the
stromal and epithelial tissues within the prostate, leading to enlargement of the
organ (Hollander and Diokno 1996). Studies have shown that 50% of all males
in their fifties and 90% of males in their nineties exhibit some pathological
evidence of BPH (Berry et al. 1994). This pathological condition leads to a wide
variety of clinical manifestations, with urinary tract infection, retention, hematuria,
and obstructive uropathy among them (Hollander and Diokno 1996). A quarter
of all men aged 55 present with BPH-related urinary flow rate reduction. This
number increases to 50% in men aged 75 (Arrighi et al. 1990). The high
incidences of both prostate cancer and BPH have prompted a large amount of
investigation in diagnosis and treatment of these diseases. For BPH, the
majority of research is focused on treatment, as diagnosis of BPH is fairly
straightforward. Prostate cancer, however, is a much more complicated
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disorder. Diagnosis of prostate cancer is a continually evolving field plagued
with problems of missed diagnoses, false positives, and understaging (Garnick
and Fair 1996a). In 1994, the FDA approved the non-invasive prostate specific
antigen (PSA) test which today is the subject of much debate as the low
specificity test has lead to numerous unnecessary biopsies and follow-up
imaging. An equally alarming problem in prostate cancer diagnosis is
understaging. Studies indicate that as many as 50% of patients who had initially
been diagnosed with organ-confined disease showed histological evidence of
metastatic diseases after initial treatment. Some of these shortfalls in prostate
cancer diagnosis may be overcome if an optimal treatment for all stages of
prostate carcinoma can be developed.
1.2 Treatments
Treatment modalities for BPH include pharmacological agents,
transurethral resection, prostatectomy, hyperthermia, ablation, transurethral
stents, and balloon dilation. Patients presenting with BPH are initially treated
medically with agents such as finasteride which lower testosterone levels and
thus cause the prostate to shrink in size. Long term studies with finasteride, the
only FDA approved hormone related therapy, have shown poor efficacy.
Although the drug has few side effects, a 5% impotence rate among them, it took
some patients up to 12 months to respond and many never responded to
treatment (Stoner 1994). If pharmacological treatments fail, transurethral
resection of the prostate (TURP) is performed. TURP has long been the "gold
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standard" treatment for BPH, yielding symptomatic improvements in 80 to 90% of
the cases (Hollander and Diokno 1996). The procedure, however, has a high
complication rate; studies indicate that rates vary from 18 to 33%.
Complications and side effects include postoperative hemorrhage, hyponatremia,
post operative clot retention, urinary tract infection, urine retention, erectile
dysfunction, and retrograde ejaculation. If problems persist after TURP, radical
prostatectomy is performed as a definitive treatment for BPH, but the procedure
is significantly more invasive and riskier than the other methods.
Treatments for prostate cancer include hormonal therapy, radiation
therapy, radical prostatectomy, brachytherapy, and cryosurgery. Treatment is
based on the cancer staging. Organ-confined tumors, classified as T1 or T2, are
typically treated by radical prostatectomy alone or in conjunction with hormonal
therapy while tumors that have spread beyond the prostate, classified as T3-T4,
N, or M, are treated by some combination of radiation, hormonal and
chemotherapies (Garnick and Fair 1998). All of these therapies have side
effects. As high as 70% of patients that undergo radiation therapy and
prostatectomy experience impotence, while 2-15% of patients experience mild to
severe incontinence. Despite the high incidence of side effects, prostatectomy
continues to be the definitive treatment for organ-confined prostate cancer as the
treatment has the highest long-term survival rate, approximately 70% over 10
years (Frohmuller and Theiss 1995; Garnick and Fair 1996b). Although
therapies for both BPH and prostate cancer are fairly well established, these
therapies are by no means optimal. Patients with these prostate diseases would
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benefit tremendously from the development of a more effective, safer, and less
invasive treatment.
1.3 Thermal Therapies for Prostate
Among the many alternative therapies being investigated, thermal
therapies of the prostate, such as hyperthermia and thermal ablation, show
considerable promise. Hyperthermia refers to mildly heating localized regions of
tissue (42-45*C) for a long duration (15-60 minutes). As a cancer treatment,
hyperthermia has been shown to cause cell death directly (Dewey et al. 1977;
Strobehn 1984) as well as indirectly by enhancing the cytotoxic effects of
radiation therapy (Dewey et al. 1977; Overgaard 1989)and chemotherapy (Hahn
1979). For prostate hyperthermia, temperatures in the prostate volume (4-6 x 4
x 2 cm3) should be elevated 5-8*C while limiting the temperature elevation in the
surrounding tissue to less than 5 degrees. Hyperthermia treatments have been
investigated clinically and have shown promise for the treatment of both BPH
(Stawarz et al. 1991) and prostate cancer (Strohmaier et al. 1991; Fosmire et al.
1993).
Thermal ablation, also referred to as thermal surgery, is used clinically to
necrose both malignant and benign tissues. During ablation treatments,
temperatures in a small localized region, typically 1-3 mm3, are elevated to 60-
100C for durations of 1 minute or less. Thermal ablation techniques have been
studied for decades; studies from the mid 2 0th century have shown that focused
ultrasound can create precise lesions without injury to surrounding tissue (Lynn
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et al. 1942; Fry 1954). Thermal ablation can be used to treat BPH by necrosing
tissue adjacent to the urethra to relieve urinary tract obstruction. Thermal
surgery techniques can naturally be extended to treat prostate cancer. Tumors
demarcated by imaging can be treated with precise focusing of thermal energy or
the whole prostate can be necrosed, effectively performing a prostatectomy.
This second therapy, thermal prostatectomy, would have an immediate impact
on prostate disease management, as it would provide the definitive treatment for
both BPH and non-metastatic prostate cancer without the complications and
invasiveness associated with conventional surgery.
Several therapies employ electromagnetic energy to thermally ablate
tissue in the prostate. The majority of these treatments are used to ablate small
volumes of prostate tissue. The most common of these methods is TURP,
which employs RF energy at roughly 240 watts to necrose tissue transurethrally.
Transurethral electrovaporization is another technique that employs RF energy,
but at higher powers to vaporize tissue (Vaportrode, Santa Barbara, CA). Studies
with the Vaportrode have shown that BPH treatments can be done with fewer
side effects and shorter operating times than TURP (Kaplan 1993). Lasers have
also been investigated to treat BPH; transurethral ultrasound guided laser
prostatectomy (TULIP) has been shown to be effective in necrosing the prostate
tissue that immediately surrounds the urethra (Anson et al. 1993). Although the
laser can be aimed accurately, urologists have difficulty visualizing the treated
region. Microwaves have also been used to treat the prostate at both
hyperthermia and thermal surgery temperature ranges. Transurethral
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applicators designed for thermotherapy can focus energy into the prostate
volume while reducing the discomfort associated with heating the prostatic
mucosa. Studies with these devices have been shown to objectively improve
urinary flow rates and other BPH symptoms (Devonec et al. 1993). Microwave
hyperthermia applicators have been designed to provide uniform heating to
larger volumes of the prostate. These microwave antennas are encased in
transrectal applicators so that larger volumes of the prostate can be heated while
reducing the urinary tract related complications associated with transurethral
devices (Strohmaier et al. 1991; Stawarz et al. 1991). Microwave phased array
antennas have sharpened the power deposition patterns (Short 1980; Diederich
and Stauffer 1993) and increased the penetration depth (Hand 1986; Lee 1992)
compared to conventional microwave antennas. However, even these refined
antennas have problems with creating focused heating fields deeper than 3 cm
at an operating frequency of 915 MHz (Fenn 1993). Although all of these
electromagnetic therapies show promise for thermal treatments, electromagnetic
waves lack the ability to focus thermal energy into deeper regions (>3 cm from
the source) of tissue. As a result, their use has been restricted primarily to BPH
treatment.
1.4 Focused Ultrasound Surgery
1.4.1 Advantages
Focused ultrasound surgery (FUS) utilizes high intensity focused
ultrasound to cause coagulative necrosis in tissue. At therapeutic frequencies,
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0.5 to 4 MHz, ultrasound can be tightly focused with little power deposition in the
near field. A typical ultrasound wave at 1.0 MHz has a wavelength of 1.5 mm
and a penetration depth of roughly 10 cm (Hynynen 1990) in soft tissue. In
comparison, a microwave, which radiates at 2450 MHz has a wavelength of 1.8
cm and a penetration depth of only 1.7 cm in tissue (Johnson 1972).
Ultrasound has been investigated for treatment by several researchers in
several organ systems, with breast, liver, prostate, and brain among others
(Szent-Gorgyi 1933; Horvath 1944; Burov 1956a; Burov and Adreevskaya
1956b; Oka 1960; Lele 1975; Lele 1967; Fry and Johnson 1978; Frizzell et al.
1977; Vallancien et al. 1993; Sanghvi et al. 1996; ter Haar 1995; Crum and
Hynynen 1996; Prat et al. 1995). Ultrasound can cause tissue necrosis via two
methods: 1) thermal energy absorption and 2) the implosion of cavitation bubbles
induced by higher pressure ultrasound waves. Although the cavitation mode
shows potential (Hynynen et al. 1996b; Lele 1977; Prat et al. 1994; Sanghvi
1998), the thermal mode is better characterized as it yields lesion sizes and
shapes predicted by models (Fan and Hynynen 1996; Damianou et al. 1995). In
addition, therapy in the thermal regime is easily monitored with thermometry.
1.4.2 Recent Advances
As early as the 1930s, investigators, encouraged by the potential of X-ray
therapy of cancers, explored ultrasound as a treatment modality (Szent-Gorgyi
1933; Nakahara and Kabayashi 1934; Horvath 1944; Lynn et al. 1942). These
initial studies showed mixed results as some trials even demonstrated that
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ultrasound induced cancer growth. These early studies and even the
subsequent trials in the 1950s and 1960s that demonstrated the feasibility of
ultrasound in vivo were limited technological in three main areas: image
guidance, ultrasound transducers, and ultrasound driving systems.
Early ultrasound treatments lacked visual and thermal feedback, which made
focusing the ultrasound at the desired location and monitoring thermal dose
during treatment extremely difficult. These visualization techniques for both
localizing the diseased tissue and then monitoring temperatures during treatment
have evolved only recently. Several investigators have used ultrasonography for
guidance (Fry 1968; Madersbacher et al. 1995; Sanghvi et al. 1999; Sheljaskov
et al. 1997), but ultrasound thermometry is unreliable due to the speed of
sound's dependence on temperature. Some have used CT for both focus
localization and thermometry (Fallone et al. 1982; Jenne et al. 1997). However,
MRI is the optimal imaging modality as both guidance and thermometry with high
spatial and temporal resolution is possible. MRI provides excellent soft tissue
contrast for diseased tissue segmentation, while temperature sensitive pulse
sequences can be used to measure relative temperature changes with an
accuracy of ±0.50 C (Ishihara et al. 1992; Chung et al. 1996; Samulski et al.
1992). Several studies have shown the feasibility of MRI-guided ultrasound
surgery in vivo (Cline et al. 1995; Hynynen 1996a; Parker 1984; McDannold et
al. 1998; Stepanow et al. 1995).
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Therapeutic transducer technology has also evolved dramatically over the past
two decades, mainly with the advent of phased array transducers. Ultrasonic
phased arrays consist of multiple ultrasonic generators, piezoelectric elements,
arranged in a specific geometry. The phase and amplitude of each generator is
varied by the electronic driving system to shape the acoustic field. Phased
arrays allow for beam steering. This provides a remarkable advantage over
single element transducers, as foci can be moved by electronically varying the
phase and amplitude of the driving signal. The higher field controllability afforded
by phased arrays also allows for sidelobe reduction, minimizing the effects of
secondary foci in the acoustic field. In many of the early FUS studies mentioned
above, single element spherically curved transducers were used to geometrically
focus ultrasound for ablation. With phased arrays, we are no longer limited to
geometries that have fixed foci. For example, planar transducers can be phased
to create different focal patterns. Phased arrays were first used in diagnostic
transducers in the late 1960s and early 1970s for improved beam steering
(Somer 1968; Thurstone and von Ramm 1974). Although early studies
suggested phased arrays would improve treatment (Lynn et al. 1942; Fry and Fry
1960), therapeutic phased arrays were not developed until the early 1980s when
Do-Huu and Hartemann used phased arrays for localizing hyperthermia
treatments (Do-Huu and Hartemann 1981). Their phased array applicator
demonstrated that transducers diced into concentric rings could scan the focus
along the axis of the transducer. Since then various investigators have
developed arrays with different geometries for both focused ultrasound surgery
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and hyperthermia. The original single element spherically curved transducer
has been sliced and diced into different geometries, and linear, tapered, and
other types of planar arrays have been developed to control different aspects of
the acoustic field (Cain and Umemura 1986; Frizzell et al. 1985; Benkeser et al.
1987; Ocheltree et al. 1987; Ebbini et al. 1988; Fjield and Hynynen 1997; Hand
et al. 1993).
The primary challenge associated with ultrasonic phased arrays is the
difficulty in array construction; however, advances in array fabrication have made
construction of these arrays more routine. Some of these advances are directly
borrowed from the semiconductor and electronics industries. Tools for
transducer dicing, critical for planar phased array construction, are the same
tools used for wafer dicing in the semiconductor industry. Both diagnostic and
therapeutic ultrasound have also benefited from the advances in the electronic
interconnect industry. Kapton flexible interconnects are now used routinely to
connect diagnostic transducers to the driving and receiving hardware.
Advancements in adhesive technologies have also influenced the rise of phased
arrays. Improved epoxies, silicones, and polymers have helped preserve the
structural integrity and water seal of the phased arrays' diced elements while
reducing interelement coupling. Phased array construction has been further
aided by piezocomposite transducer materials. Composite materials contain
small piezoelements embedded in polymer. They can be molded into any shape
and dimension. Instead of requiring dicing, the electrode layer of these materials
can be etched away to create the elements of the phased array. This avoids the
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need for precision cutting and adhesives. However, piezocomposite elements
are less efficient than diced elements as piezocomposites have higher
interelement coupling. Generating high powers with these elements is more
difficult than in conventional diced phased arrays. Nevertheless, piezocomposite
phased arrays have been successfully used to create lesions in porcine liver
tissue (Daum and Hynynen 1998b).
1.5 Other Prostate Array Designs
Ultrasound arrays for treating prostate disease have evolved from
unfocused transducers for hyperthermia to large-scale phased arrays for
prostate ablation. Initial attempts at prostate disease treatment were done with
unfocused transducers. One of the first systems used diced cylindrical elements
in an intracavitary applicator for hyperthermia treatments (Diederich and
Hynynen 1990). Fosmire et al. showed that these unfocused intracavitary
arrays could be used clinically for treating prostate adenocarcinoma (Fosmire et
al. 1993). These early attempts were limited by poor control of power deposition
in the depth dimension. Because of this limitation, higher acoustic powers were
needed to reach therapeutic temperatures. In a unfocused transrectal
hyperthermia system it was found that for an applicator with cylindrical geometry
(1.5 cm diameter) and frequency of 1.5 MHz, a minimum acoustic
power/transducer length of 12 W/cm was needed to achieve hyperthermia
temperatures (Hynynen 1990). Despite requiring large powers for efficacy, these
first arrays did set a precedent for transrectal applicator design. Although
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transurethral designs have been proposed (Diederich and Burdette 1996), most
ultrasound prostate therapy transducers have been housed in intracavitary
applicators. Intracavitary applicators bring the energy source close to the target
volume, thereby minimizing normal tissue exposure. In addition, transrectal
ultrasound delivery to the prostate is free of bone or air, both of which are
barriers for ultrasound propagation.
Radial
~ Axial
Transverse
Figure 1-1. Schematic of Cylindrical element transducer in a transrectal
applicator.
To combat poor power deposition in both the depth dimension and the
axial dimension, phased arrays were proposed. In one study, a series of
acoustic field/thermal simulations were performed to optimize element width ( k/3
to 5X/3 center-to-center), focus location (depth, center versus off axis),
frequency(0.5 MHz to 2.0 MHz), and phased array length (3.75 cm to 10 cm)
(Diederich and Hynynen 1991). From these simulations, a 40-cm long array with
180* cylindrical elements spaced 0.85k center to center was constructed. While
the array was not clinically suitable due to significant side lobe structure (~40%
power deposition) and short phased array length, it did show that electrical
focusing of ultrasound into tissue 2 to 5 cm deep was feasible with an
intracavitary array. Subsequent arrays attempted to reduce side lobe structure
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by increasing the number the elements in the phased array. A 64 element
cylindrical array with 0.58k center to center spacing, 11.05 cm long, operating at
0.5 MHz was constructed (Buchanan and Hynynen 1994). This array performed
better than previous attempts, but -20% grating lobes still existed when focusing
2.5 cm off axis at 4 cm depth. In this study, focused ultrasound experiments
were also performed. In ex vivo perfused kidney, the array was able to elevate
temperature at the focus only 120C, which is insufficient for ablative treatment.
While cylindrical elements conformed to the geometry of transrectal
applicators and were adequate for hyperthermia, newer transducer geometries
were needed to reduce grating lobes and to create the higher intensity focal
patterns for ablation. To deliver higher powers at fixed focal distance, spherical-
sectioned arrays were developed for transrectal treatment of the prostate. These
transducers were able to successfully ablate human prostate (Madersbacher et
al. 1994) tissue producing 10 mm lesions at fixed distances from the array. And
in perhaps the largest multi-site clinical trial for ultrasound BPH treatment,
transrectal spherical-sectioned arrays of varying focal length, 2.5 to 4.5 cm, were
used to treat benign prostatic hyperplasia (Sanghvi et al. 1999). In the study, a
rectangular 30 x 22 mm cut-out from a spherical transducer operating at 4 MHz
was used for therapy and imaging. The transducer is divided in two with a center
11 mm circular segment used for pulse-echo imaging, and an outer annulus
which is used in conjunction with the center segment for focused ultrasound
treatment. The transducer housed in the intracavitary applicator can be
21
mechanically translated and rotated along the axis for greater prostate volume
coverage. However, different arrays with different focal lengths are needed to
move the focus in the depth dimension. Almost all of the 62 patients in the
study showed significant improvements in peak urinary flow rate, International
Prostate Symptom Scores (IPSS), and quality of life scores (QOL) over a 2 year
period with few complications and no injury or side effects. The treatment is a
safe and durable alternative to TURP for BPH, but ablating large prostate
volumes for prostate cancer treatment is not feasible with this array. Secondly,
the fixed focus transducer can only be used for ablation, and cannot be used for
hyperthermia.
Fixed focus transducers have also been used in transrectal prostate
cancer treatments (Gelet et al. 1999). In this study, 50 patients were treated for
localized prostate cancer. The treated patients were followed for a median of 24
months, and based on PSA levels and sextant biopsy results, 56% of patients
were in complete remission. The remainder of the patients were grouped into 3
groups: patients who failed the PSA test (6%), patients who had positive
biopsies(18%), and patients who failed both tests on follow-up (20%). The
problem with treating localized prostate cancer is previously discussed
understaging issue. Too often, the degree of prostate cancer is underestimated,
so local ultrasound ablation might not treat all neoplastic regions. Patients who
were diagnosed with localized prostate cancer could have had cancer nodes in
other areas of the prostate. Although the study shows that focused ultrasound
could be used to treat prostate cancer with minimal side effects, the results
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indicate that treating localized prostate cancer with fixed focus transducers is not
the optimal approach for treating prostate cancer.
Y
Z M- R0cm
Figure 1-2. Diagram of an eight sector spherical-sectioned transducer.
Linear planar arrays were proposed as an another alternative (Hand et al.
1993). Prototype planar arrays for prostate therapy have been fabricated and
tested in phantoms (Bechtold et al. 1997). This array geometry has advantages
over both cylindrical-sectioned and spherical-sectioned arrays. Compared with
cylindrical arrays, linear arrays do not have the 1/r acoustic intensity loss, and
their heating fields do not increase in cross-sectional area as radial distance from
the array increases. Linear arrays trade off the high gain natural focus of
spherical-sectioned arrays for the ability to electronically move the focus. Thus,
these arrays need to be driven at higher powers for equivalent thermal dose.
Critical to the generation of high intensity foci is minimization of grating lobe
structure. Linear phased antenna theory, developed initially for radar phased
arrays, states that a linear array with a regular center-to-center spacing of 1/2 or
less is perfectly steerable with no grating lobes along the axial and radial
dimensions of the array. In ultrasound phased arrays, this geometry would
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require elements on the order of 0.5 mm in width for 1.5 MHz transducers.
Smaller elements mean increased difficulty in array construction, specifically in
wiring and sealing. In addition, more elements would be needed to cover the
same tissue volume, which would impose greater demands on the ultrasound
driving system requiring more amplifier channels and phase shifters. Another
disadvantage is that acoustic efficiency, the ratio of output acoustic power to
input electrical power, decreases as element width decreases (Hynynen 1994).
U LRadial
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Figure 1-3. Diagram of a linear phased array.
For these reasons, irregular linear geometries have been investigated.
Center-to-center spacing greater than k/2 can be used if array periodicity is
eliminated (Skolnik 1980). An extensive simulation study of aperiodic, tapered,
and sparse linear geometries has shown that aperiodic arrays produce the
lowest grating lobe levels (Hutchinson 1997). An optimal 57 element aperiodic
array with two different element widths ordered randomly was fabricated and
evaluated (Hutchinson et al. 1996). The array's two different element widths,
array length, and element ordering were determined from a cost function
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analysis, which favored geometries with low grating lobe levels. The fabricated
array demonstrated that grating lobe levels can be reduced 30%-45% as
compared to periodic arrays and that the average element width can be
increased (20%-35%) over their periodic counterparts without an increase in
grating lobe levels. In a subsequent study, a 62 element aperiodic array was
incorporated into a intracavitary applicator, and in vivo and ex vivo experiments
were performed with MRI thermometry (Hutchinson and Hynynen 1998). The
study showed that small 4 mm x 4 mm x 7mm lesions could be created in in vivo
rabbit thigh muscle and that MRI compatible intracavitary planar arrays could be
used for ablation. However, since the Hutchinson array is linear, the focus can
only be steered in 2 dimensions, along the radial and axial axes. The inability to
move the focus in the transverse direction makes complete coverage of the
prostate volume difficult.
1.6 Scope of This Thesis
In order for focused ultrasound surgery to become an accepted treatment
method for prostate cancer, ultrasound arrays that can ablate large prostate
volumes need to be developed. The primary goal of this research was to
develop and test an intracavitary ultrasound phased array capable of whole
prostate ablation. The study was conducted in series of three steps.
In the first portion of this study, phased array fabrication and manufacturing
techniques were investigated. Current techniques are such that array reliability
and power output are not adequate for clinical treatments. Various transducer
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interconnect methods, wire bonding, Kapton printed circuits, and soldering
schemes, were evaluated to reduce interelement crosstalk and to improve power
output. In addition, alternative grounding techniques were investigated as poor
grounding schemes have plagued phased arrays. Leaking of water into the back
compartment of the transducer has also been a problem, so water sealing
methods were also studied.
Then, with the optimal fabrication techniques, the intracavitary phased
array was constructed. PZT-4 transducer material was diced to the Hutchinson
62 element aperiodic linear geometry to minimize grating lobes. The phased
array transducer was housed in a transrectal applicator, which utilizes an
ultrasonic motor to provide up to a 100-degree mechanical rotation angle to the
1 D transducer array. The rotation axis provides a mechanical means of
scanning the focus in the transverse direction, thus allowing complete 3D
scanning of the high intensity focus. The complete device was also designed to
be MRI compatible for use with MRI thermometry and guidance. The array was
driven by a multi-channel ultrasound amplifier system with power and phase
feedback circuitry designed to improve thermal focusing.
In the final portion of the study, MRI guided in vivo and ex vivo
experiments were performed to verify the array's large volume ablative
capabilities. Experiments in ex vivo bovine phantom were used to evaluate the
volume extents of the arrays focusing capabilities. In vivo rabbit thigh
experiments were used to test the array's ability to create large lesions in short
treatment times.
26
2 Ultrasound Array Fabrication and Array Materials
2.1 Introduction
2.1.1 Array Requirements
One facet of this study was to improve upon the current materials and
manufacturing techniques used in creating linear ultrasound phased arrays for
thermal therapy. The basic requirements of these arrays are as follows. The
array must be capable of delivering high acoustic powers, approximately 50-60
wats, reliably without sustained damage to the transducer or the applicator.
Second, inter-element electrical and mechanical coupling must be minimized.
Third, the arrays must be able to withstand prolonged submersion in water as
this is the medium that couples the transducer to the tissue. Fourth, the array
should be MRI compatible, so that treatment can be done with MRI guidance
and thermometry. This section of the thesis will discuss the materials and
manufacturing techniques investigated to meet these transducer requirements.
2.1.2 Current State of Array Fabrication
One dimensional phased arrays for therapeutic ultrasound are usually
developed from a single rectangular PZT(Lead Zirconate Titanate) piezoelement.
The PZT pieces are sputtered with a thin silver, copper, or gold electrode layer to
provide a means for electric field application. Typically, these stock pieces are
diced into the desired geometry, and the spaces between the elements (kerfs)
are filled with silicones, epoxies, or other polymers. The filler material is selected
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to minimize mechanical and electrical coupling between elements while
maintaining the structural integrity of the phased array transducer. Once the
transducer is diced, filled, and mounted into a frame, electrical connections to the
elements of the phased array are made. Ground connections are made on the
transmission side of the transducer and the high voltage signal lines are
connected on the back face to minimize patient exposure to high electrical
currents. Therapeutic transducers must transmit high levels of power for
extended periods of time. For these reasons, the piezoelements are backed with
a low impedance media on the back face to minimize backward transmission and
sometimes coated with a quarter wave acoustic matching layer on the
transmission side to minimize reflections in the forward direction. Air makes an
ideal backing for therapeutic transducers as it eliminates backward transmission
without increasing inter-element coupling (Wells 1977; Hynynen 1990).
Continuous matching layers, on the other hand, increase inter-element coupling,
and for many array geometries, they are avoided as the disadvantage of
increased coupling outweighs any gains from the matching layer.
High demands are also placed on the electrical connections of therapeutic
transducers. These connections must be able to handle large RF currents and
voltages on the order of amps and hundreds of volts with minimal loss and must
not transmit noise to or pick up noise from the MRI system. In addition,
electrical interconnects should not contain iron based materials, and must
minimize the amount of metal overall as MRI images are susceptible to metal
artifacts. And, from a handling and construction perspective, the wire diameters
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and interconnect dimensions should be small. Currently available micro coaxial
cable satisfies these criteria, and a large variety of coaxial cables have been
tested for use in therapeutic arrays (Daum 1998).
The Hutchinson array represents the state of the art in therapeutic linear
phased arrays; many of the materials and manufacturing techniques mentioned
above were used in this array (Hutchinson and Hynynen 1998). Extensive tests
of filling adhesives were performed for this array (Daum 1998). The silicone (VI-
SIL V-1022) used in filling this array performed well in high power, water
immersion, coupling, and adhesion force tests. The entire array assembly,
consisting of transducer, cables, and array holder, was MRI compatible. The
array was also able to deliver the powers needed for ablation of the prostate, up
to 180 watts of electrical power with acoustic efficiencies in the mid 40% range.
However, at sustained high powers, the array leaked water, and the ground
plane integrity was compromised. Water in the back of the transducer eliminates
the low impedance air-backing and also increases the electrical coupling as the
water provides a medium for crosstalk between the signal lines. In addition,
wiring of the array in the transrectal applicator was extremely difficult. The wiring
for 62 phased array elements was packed in a semi-circular area with a radius of
1 cm. The packaging of wires in this small area also increased the crosstalk
between signal lines to the phased array element.
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2.2 Methods and Materials
2.2.1 Test Array Construction
A series of 8-10 element test arrays were constructed to address the
material and manufacturing shortfalls of the Hutchinson array: grounding,
waterproofing, and wiring. Each test array was fabricated from 1.1 MHz PZT-4
pieces (EDO EC-69, Salt Lake City, UT). To match the element sizes of the
proposed array, rectangular PZT pieces were diced into 15 mm X 1 mm and 15 x
1.15 mm elements with kerf size of 0.11 mm (NIH Transducer Resource Center,
Penn State University, PA). Before dicing, the PZT stock piece was fixed onto a
glass surface with either wax or Nitto tape. Kapton tape (3M, St. Paul, MN) is
attached on the exposed surface to protect the electrode surface during the later
filling phase. Then, the PZT was diced all the way through to the wax or Nitto
tape with a diamond-impregnated blade mounted on a wafer dicing saw (K & S
782).
Once the PZT is diced, the kerfs were filled with degassed two-part (50:1)
VI-SIL V-1 022 silicone (Loctite Corp.). The silicone was poured onto the Kapton
protected surface and kneaded into the kerfs. Each test array was then mounted
in a polycarbonate frame with V-1022 silicone. After the silicone cured, typically
24 hours, the Kapton tape was removed to expose the electrode surface, and
the surface was cleaned with steel wool (Figure 2-1a). Then, the electrical
connections were made to the transducer, and the different sections of the
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polycarbonate housing were glued together with RTV-1 08 (General Electric
Silicones, Waterford, NY) to maintain a hermetic seal (Figure 2-1).
Frame
ac
transducer
L
Silicone
lines Flex Circuit
Ground pad
I Ground plane
Front Face
Figure 2-1. Schematic showing test array construction at different stages (a-c).
The schematics show the back face and the side cross-sectional views of the
test array at each stage. The flex circuit is shown in (b). The front face is also
shown for the completed test array (c).
2.2.1.1 Kapton Flexible Circuit Interconnect
To address the wiring issues, a Kapton flexible interconnect was
developed. There are multiple advantages to utilizing flexible printed circuit
interconnects. First, a high density of wires can be packaged into a very small
area. Second, printed circuits reduce signal line crosstalk, and circuits can be
designed to handle large currents and voltages. In addition, the flexible
interconnect makes the task of wiring easier. The interconnect was designed
with three main criteria: 1) all signal lines must be able to handle up to 500 V,.
31
without breaking down 2) all lines must sustain currents up to 25 mA rms ; 3) the
interconnect must have a cross sectional area no larger than a 5 mm radius
semicircle. Based on these criteria, an 11-line flexible printed circuit with a
ground plane was fabricated (Advanced Electronics, Minneapolis, MN). The
signal lines were made with 2 ounce copper, and the interconnect has cross-
sectional dimensions of 8 mm X 0.2 mm. All solder pads were gold plated to
provide an optimal surface for soldering or gold wire bonding. Multiple flexible
circuits could be layered to provide connections for additional elements.
The flexible circuit was mounted to the transducer frame and connected to
the transducer elements with standard 30 AWG wire-wrap wire via soldering
(Figure 2-1b). Gold wire bonding was investigated as a method for connecting
transducer elements to the Kapton interconnect, but the 1 mil and 3 mil diameter
wires tested were too brittle. In addition, gold wire bonds adhered well to the
gold plated electrode of the flex circuit, but connected poorly to the silver
electrode on the transducer. Silver wire bonding was also attempted, but again
these wires were weak and adhered poorly to the silver electrode of the
transducer. For these reasons, transducer elements were soldered to the flex
circuit rather than gold wire bonded. Soldering was done at 550 *F, below the
Curie temperature of the PZT piezoelements. Low capacitance micro-coaxial
cables (32 AWG, Precision Interconnect, Portland, OR) were soldered to the
other end of the flex circuit to provide an extended 7 meter cable assembly to the
ultrasound amplifier system. The cable assembly was interfaced to the driving
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system through a DL connector (ITT-Cannon, White Plains, NY) which was
chosen to minimize cable reflections.
2.2.1.2 Ground Plane
Grounding the elements of transducers has historically been a problem in
phased arrays with numerous small elements. When grounding small elements,
the major issue is providing a solid ground plane without mechanically coupling
the elements of the transducer. In the Hutchinson array, two grounding
techniques were used: 1) the transducer was diced 85% through, and so all the
elements were grounded through the intact face; 2) each element was
individually soldered to ground. In the first technique, the 15% undiced PZT
segments cracked at high powers. The soldered wire technique was rejected
because it was not durable over a series of experiments.
In this study, test arrays were used to evaluate different grounding
techniques. In all the test arrays, thin planar sliver sheets were attached to front
face covering only a small portion of the transducer face (Figure 2-1c). The
silver sheet was passed through the transducer housing and soldered to the
ground pad of the flex circuit. Three different ground plane techniques were
tested. In one test array, silver conductive tape (3M, St. Paul, MN), was
attached to the front face. In other arrays, conductive epoxies (Mereco
Medaduct 1202, West Warwick, RI, and Tra-con, Bipax, Medford, MA) were used
to attach silver foil (0.025mm thickness, Aldrich Chemical, Milwaukee, WI) to the
transducer ground electrodes. Soldering of silver foil directly to the transducer
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electrodes was also tested. In this technique, the silver foil was pre-tinned with a
very thin layer of solder using solder flux. The foil was attached to the
transducer ground electrodes by pressing the foil to the electrodes with the hot
soldering iron. This created a very thin and strong connection between the
ground electrodes and the silver foil. Test arrays with all ground plane methods
were fabricated, and acoustic efficiency, maximum power, and coupling tests
were performed to gauge the performance of the different grounding techniques.
2.2.1.3 Water Sealing
As discussed previously, water leaking to the back of transducer has been
a problem in previous large-scale phased arrays. Water can leak in through gaps
in the housing, through the silver foil or flex circuit exit slots, or through the kerfs
in between the transducer elements. Leaking can become a more significant
problem at high powers. When the transducer elements are vibrating at high
amplitudes, negative pressure builds in the rear chamber of the transducer
housing. This aids in pulling water in from the coupling bath, and water tends to
collect even when only a minute leak is present. A wide variety of silicones,
epoxies, and polymers (VI-SIL V-1022, RTV-1 08, Goop, & polyurethane glues)
can be used to seal the gaps in the housing or gaps in the exit ports of ground
plane and flex circuit, but leaking through the kerfs is a more complicated issue.
To fix this problem, epoxy encapsulates were tested. The transmission face of
each test array was coated with encapsulates to protect kerfs from water. Prior
to the application of epoxy, the transducer face was cleaned thoroughly with
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xylol and steel wool. Then, care was taken to apply a very thin layer of epoxy to
the transducer face. Three epoxies were tested, Mereco 1650, Mereco 1670,
and Mereco 401 ST (West Warwick, RI). These epoxies had been used to coat
other ultrasound transducers. Acoustic efficiency, maximum power, and
coupling tests were performed with all three materials to verify the encapsulates'
effect on ultrasound transmission.
2.2.2 Acoustic Efficiency measurements
Acoustic efficiency is the ratio of input electrical power to output acoustic power.
The transducers were driven with a custom designed ultrasound amplifier system
(Daum et al. 1998a) or an ENI power amplifier (ENI, Rochester, NY). The
acoustic power measurements were made using a radiation force technique
(Stewart 1982). The electrical power measurements for individual array
elements were made using either a HP 438A Power Meter (Hewlett Packard,
Englewood, CO) or the custom built power meters on the ultrasound driving
system. Efficiency measurements for powering the entire array simultaneously
used the custom-built power meters for each individual element attached to the
driving system.
2.2.3 Maximum Power measurements
The maximum acoustic power was measured by progressively increasing the
electrical power to an array element and measuring the acoustic output power
until acoustic efficiencies began to drop more than 10%. Thus, maximum power
recorded in the tables below is maximum sustainable power per element.
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Efficiency measurements were again recorded at lower powers to measure the
effect of high powers on the transducer elements. Peak power measurements
were performed on all arrays that didn't fail in prior testing.
2.2.4 Coupling measurements
Inter-element coupling was tested by measuring the acoustic efficiency when
adjacent array elements were electrically driven in-phase and out-of-phase. For
in-phase measurements, all elements of the transducer were powered in phase
with the custom-built amplifiers. For out-of-phase measurement, every element
was driven 1800 out of phase with its neighbor. Acoustic efficiency
measurements for the whole array were made as described in the section above.
The difference in the in-phase and out-of-phase efficiency measurements gives a
measure of the inter-element coupling. Coupling measurements were performed
on test arrays that had high acoustic efficiencies.
2.3 Results
2.3.1 Ground Plane
Table 2-1 shows the acoustic efficiency, maximum power measurements, and
coupling measurements for the different grounding techniques evaluated in this
study. Data from the Hutchinson array is provided to gauge the level of
improvement in each of the different construction techniques. All the test arrays
used to evaluate the grounding techniques, except those using silver tape,
incorporated the Kapton flexible interconnect. The silver tape arrays used the
same wiring scheme as the Hutchinson array: 30 AWG wire soldered to the
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elements which were then soldered to coaxial cable to provide the 7 meter
extension. In all cases, element acoustic efficiencies represent an average value
for all tested elements near maximum acoustic powers. Maximum power
measurements listed are values just prior to failure. Failure modes varied for the
different arrays. The silver tape array and both silver epoxy test arrays failed
due to ground plane detachment. In the soldered ground plane case, the
elements probably failed due to depoling; there was no evidence of electrode
detachment, arcing, or element cracking. In the two better forming grounding
techniques, coupling measurements were performed in mid power ranges, not at
the maximum power levels. In both cases, the out-of phase acoustic efficiencies
were 9% lower than then the in-phase measurements, yet the out-of-phase
coupling was still on par with the in-phase measurements of the Hutchinson
array.
Table 2-1. Efficiency, maximum power, and coupling measurements for different
ground plane techniques
Grounding Element Acoustic Maximum Inter-Element
Technique Efficiency Acoustic Power Coupling
per element
In Out
Hutchinson Array 46% 3.5 watts 42% 41%*
Silver Tape on Failure
edge
Silver Tape on 15% 300 milliwatts
whole surface
Tra-con Bipax 27% 1.1 watts
Mereco 1202 49% 3.6 watts 51% 42%
Soldering 60% 11.4 watts 58% 49%
*The out-of-phase measurement in the Hutchinson array is with the array
focused at 5 cm distance radial to the array.
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2.3.2 Encapsulates
Table 2-2 shows acoustic efficiency, maximum power measurements, and
coupling measurements for the encapsulates evaluated in this study. In all the
encapsulated test arrays, the soldering grounding technique was used. Results
varied greatly depending upon the level of epoxy degassing, transducer face
cleaning, and the thickness of the encapsulate layer. The data in the table
shows the best results for each encapsulate. As with the grounding technique
data, element acoustic efficiencies are averages over all tested elements near
maximum powers. Maximum acoustic power measurements were made in 2-3
elements of the test array. Elements encapsulated with Mereco1650 showed a
dramatic drop in acoustic efficiency just beyond the peak acoustic power
recorded in the table. In the case of the Mereco1670, failure was due to
detachment of the epoxy coating from the transducer face. In the Mereco 401ST
test array, the elements would begin to overheat at peak acoustic power and the
efficiency levels would drop below 10%. The power value just prior to the drop is
listed in the table. Overheating did not cause damage to the elements as
returning to lower power levels would yield efficiency measurements recorded
earlier. Coupling measurements were done on the two better performing
encapsulated test arrays. In both cases, in-phase and out-of-phase acoustic
efficiencies differed by 8%; however, whole array efficiencies in the Mereco 1650
and 401ST were 10% and 13% (Table 2-2) lower respectively than the non-
encapsulated case (Table 2-1).
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Table 2-2. Efficiency, maximum power and coupling measurements for different
encapsulates
Encapsulate Element Acoustic Maximum Inter-element
Efficiency Acoustic Power Coupling
per element
In Out
Mereco 1650 55% 7.4 48% 40%
Mereco 1670 17% 0.5 20%
Mereco 401ST 48% 1.2 45% 37%
2.4 Discussion and Conclusions
The test array data shows clear improvements in array performance with
the new wiring and grounding techniques. Test arrays utilizing the Kapton
flexible interconnect and the soldering grounding technique performed
significantly better than the Hutchinson array in all categories, efficiency,
maximum power, and inter-element coupling. Test arrays incorporating Mereco
1202 silver epoxy and the flexible circuit performed better or on par with the
Hutchinson array in the test categories. The two most significant improvements
with these techniques are the maximum power and whole array out-of-phase
efficiency measurements. The maximum power measurements show that
elements with solder and flex circuit connections can be driven up to 3.5 times
harder without failure due to depoling or weakness in electrical interconnects. In
addition, acoustic efficiencies of these elements when phased are better than the
unphased efficiencies of the Hutchinson array. The Kapton printed circuit has
more than likely reduced crosstalk between the signal lines. For these reasons,
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both the soldering grounding technique and the flexible interconnect will be used
in the construction of the 62-element phased array.
The encapsulate data suggests that Mereco 1650 can be used to seal the
transmission face of the transducer without significant loss in performance. The
1650 epoxy, a flexible encapsulate, performed significantly better than the 1670,
a fast curing flexible epoxy, and the 401ST, a stiffer, harder epoxy. The 1650
encapsulated array also was on par or better than the Hutchinson array in all
tested categories. In addition to the water sealing abilities of these coatings, the
encapsulates also act as an electrical insulation layer confining potentially
dangerous leakage currents to the face of the transducer and not into the
coupling media. The problem with these encapsulates, however, is that test
arrays with the same coating had different test results. Consistency with the
coating technique was not established. Furthermore, the best encapsulated
arrays had acoustic efficiencies equal to the Hutchinson array, so encapsulating
negated some of the improvements gained with the new fabrication techniques.
Therefore, the 62-element phased array was not coated with any encapsulates.
If leaking through the kerfs becomes a problem later on and if coating technique
consistency improves, the 62-element phased array could be coated with
Mereco1650.
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3 Construction of Phased Array System for Transrectal
Ablation
The major focus of this thesis was the design and construction of an
intracavitary phased array for transrectal ultrasound ablation. Using the
techniques described in the previous section, a 62-element phased array was
incorporated into a transrectal applicator capable of rotating the linear array
along its long axis.
3.1 Transducer
The 62 element linear phased array was constructed from 1.1 MHz
resonant PZT-4 (EDO EC-69) with the dice and fill technique detailed in the
previous section. The array incorporates 31 1.0 x 15 mm elements and 31 1.15
x 15 mm elements that are randomly ordered (with total dimensions of 15 mm x
75 mm). The particular aperiodic geometry, i.e. the ordering, used in this array
comes from a previous simulation and optimization study that showed significant
reduction in grating lobe structure with aperiodic linear geometries (Hutchinson
1997). Acoustic simulations of this array geometry demonstrated that foci with
minimal lobe structure can be generated in a 3 cm x 6 cm area 3 cm from the
array surface (Figure 3-1).
High intensity foci are produced by electrically setting the phases of each
element so that constructive interference of the pressure waves from each
element occurs at the desired focal position. The required phase for each
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element is calculated using the differences in path length from the center of each
element to the desired focus:
$, 3= 0 (d,-d)-30 (3-1)
where $, is the phase of element i in degrees, di is the distance from the center of
element i to the desired focus, do is the distance from the center of the reference
element to the focus, i is the element number ranging from 1 to 62, and n is an
integer used to keep $i between 0* and 3600 (Figure 3-1).
6 cm
3 cm
di do
3 cm radial
axial
transverse
Figure 3-1. Diagram showing the electrical focusing capabilities of the linear
transducer. The phased array can focus ultrasound in a 3 cm X 6 cm area 3 cm
from the transducer surface.
3.2 Intracavitary Applicator
The linear phased array transducer was incorporated into an intracavitary
applicator suitable for transrectal use. The applicator was designed to satisfy
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several criteria. First, due to anatomical constraints, the portion of the applicator
that must be in the rectum was designed to be as small as possible yet large
enough to house the transducer and its wiring. Second, the applicator was
designed to be MRI compatible, so no ferromagnetic materials were used. The
amount of non-ferromagnetic metals was also minimized since they can distort
the MR images. The applicator was constructed from polycarbonate and acrylic,
and nylon screws and polymer adhesives were used in assembly. The motor
used for transducer rotation is MRI compatible. The design also incorporates an
ultrasound coupling system. The rectal portion of the applicator has O-ring slots
at both ends and water inlet and outlet lines so that a latex condom can be
attached and filled with water to couple the transducer to the rectal wall and the
underlying tissue. The circulation lines also allow temperature control of the
water bolus. The design includes leak prevention measures. Air is circulated
behind the transducer to provide small positive pressures. The circulation
prevents leaking by counteracting the negative pressures created during
sonication.
Figure 3-2 below shows a detailed schematic of the transrectal applicator.
The dimensions are in millimeters. The basic design involves an inner cylinder
that rotates within the outer housing. The transducer/frame assembly is mounted
in the inner cylinder. The outer housing at the front portion (the portion placed in
the rectum) of the applicator holds the latex condom and allows the transducer to
rotate freely without contacting the rectal wall. The inner cylinder is coupled to
the motor at the far end of the applicator. The flexible interconnect traverses the
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length of the applicator from the rectum portion to the rear compartment where it
is soldered to the 7-meter micro-coaxial cable (Precision Interconnect) extension.
Water seals were placed at the entry to the rear compartment to prevent water
from entering the rear chamber.
Figure 3-3 shows a close-up of the three components that comprise the
front portion of the applicator: the transducer frame, the inner cylinder, and the
outer housing. This section of the applicator is 21 mm in diameter and 105 mm
long. The outer housing's primary function is to anchor the latex condom;
therefore, condom securing O-ring slots were fabricated into the outer housing.
The inner cylinder serves as the transducer's mounting bed. It also houses the
water lines and all the wiring. The inner diameter of the inner cylinder is 13 mm,
which is large enough to accommodate the flexible interconnect and the water
lines. Figure 3-4 shows the rotation of the inner cylinder within the outer
housing. The transducer can be rotated 50* in both the clockwise and
counterclockwise directions.
An ultrasonic motor (Shensei USR 60-N4, Japan) was used to rotate the inner
cylinder. Like a stepper motor, its revolution can be precisely controlled; the
Shensei motor can be rotated in increments of 0.090*. The motor has no
magnetic components and can be used in the core of the MRI magnet.
However, the motor driving and matching circuitry (D4060, Litton-Westrex,
Japan) is not MRI safe, and this circuitry was placed outside the magnet room
and connected to the motor via a 7-meter coaxial cable. The motor was
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switched off during sonications since the powered motor added noise to the MR
images. The motor shaft position was tracked with a high-speed rotary encoder
(MTL ME30-10000 C, Japan). The rotary encoder provides real-time feedback
during inner cylinder rotation. A Microsoft Foundation Class (MFC) based C++
program was developed to control the motor.
45
Figure 3-2. Schematic of the intracavitary applicator. All dimensions are noted
in millimeters. The front portion of the applicator hold the transducer. The water
lines, air line, and Kapton flex circuit pass through the inner cylinder to the rear
compartment and exit the throught the slots shown. The rear compartment is
protect from water by the water seals. At the rear of the applicator, the motor is
attached to the inner cylinder.
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Figure 3-3. Close-up of the front portion of the intracavitary applicator. The
Transducer frame holds the linear phased array. The frame is attached to the
inner cylinder. The inner cylinder rotates inside the outer housing. The outer
housing has 0-ring slots for anchoring the latex condom used in the ultrasound
coupling system.
radial
axial .transverse
Figure 3-4. Illustration of the array's rotation. The transducer which is mounted
in the inner cylinder can rotate 50 "in both clockwise and counter-clockwise
direction to provide coverage in the transverse axis.
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3.3 Assembly & Operation
The diced transducer was connected to the flexible circuit and mounted to
the intracavitary applicator. Figure 3-5 shows the complete array assembly
procedure. First, the diced and filled transducer was mounted in an acrylic frame
with VI-SIL V-1022 silicone (Figure 3-5a). Then, 30 AWG single stranded wire-
wrap wire was soldered to each element of the phased array (Figure 3-5b). All
soldering was done with solder flux at 550 *F. Upon completion of the soldering,
the flexible circuit support platform was attached to the frame also with VI-SIL V-
1022 silicone(Figure 3-5c). Six pieces of the custom designed Kapton flexible
circuit, each piece containing 11 connections, were staggered and glued
together with cyanoacrylate adhesive (Liquid Krazy Glue, NY, NY). All solder
pads on the flexible circuit were covered with Kapton tape (3M) to protect the
pads from any excess adhesive. The layered flexible circuit was threaded
through the slot in the rear compartment and pulled out of the open front portion
of the application. The Flexible circuit was attached to the platform with double
sided tape reinforced with cyanoacrylate (Figure 3-5d). Then, the wires from the
array were carefully soldered to the pads of the printed circuit. Once all the wires
were attached, the transducer/frame assembly was detached from its glass
mount, and the ground plane was soldered to the transmission face of the array
using the technique described in the previous section (Figure 3-5e & f). The
transducer was then mounted in the applicator using VI-SIL V-1022 and RTV-
108 (General Electric). The RTV-108 was used after the VI-SIL V-1022 cured to
provide additional waterproofing. Figure 3-6 shows a scaled cross-section view
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of the front portion of the applicator with the transducer in place. Note that the
transducer is air-backed, and that there is ample room for the Kapton
interconnect and all the soldered wires. Air was circulated into the enclosed area
behind the transducer to maintain positive pressure.
Following attachment of the transducer, a seven-meter long micro-coaxial
cable (Precision Interconnect) assembly (62 wires terminated with a DL
connector) was soldered to the opposite end of the flexible circuit in the rear
compartment of the applicator. The flexible circuit is L-shaped; the long leg
traverses the length of the inner cylinder, and the short leg begins as the printed
circuit exits the inner cylinder in the rear compartment. Prior to soldering, the
small leg was looped around the inner cylinder once. The connected flex circuit
was then anchored in the rear compartment with electrical tape. The anchored
loop acts as a strain relief for both the cable assembly and the flexible circuit
during inner cylinder rotation. As the motor rotates, the loop tightens in one
direction and loosens in the other, preventing tension in the cable and flexible
circuit. Figure 3-7 shows this loop and the complete intracavitary applicator with
the cable assembly.
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(a)
(b)
Figure 3-5. Pictures of the array at various stages of construction. (a) shows the
transducer mounted in its frame. (b) shows the wire-wrap wires soldered to the
elements.
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(c)
(d)
Figure 3-5. Pictures of the array at various stages of construction. (c) shows the
flexible circuit support platform. (d) shows the printed circuit mounted and the
connected to the elements of the phased array.
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(e)
(1)
Figure 3-5. Pictures of the array at various stages of construction. (e) shows the
transducer/frame assembly as it is being mounted in the inner cylinder. (f)
shows the finished transducer with ground plane.
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Transducer
Solder connection
Flex Circuit Frame
Applicator
Figure 3-6. Cross-section of the applicator with mounted transducer. All the dark
regions in the drawing are regions where adhesives have been used.
Figure 3-7. Picture of the completed intracavitary applicator. Note the curl in the
Kapton flexible circuit in the rear compartment of the applicator.
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3.4 Amplifier
The array is driven by a 64-channel custom designed amplifier system
(Daum et al. 1998a). This ultrasound driving system improves the focal
intensities of the aperiodic array by up to 25% without the need for implantable
hydrophones by incorporating power and phase feedback circuitry. The
amplifier is composed of four main blocks: the control system, phase regulation
circuitry, power generation circuitry, and matching circuitry. The digital control
system takes user input via Microsoft Windows and maintains the specified
power and phase setpoints for each element. The driving frequency and other
amplifier variables are also set through the control system. The phase regulation
block incorporates a phase-locked loop to maintain the set phase at the element.
Power is generated with a separate hybrid class D/E power amplifier for each
element. The control system, power generation block, and the phase regulation
block continuously interact to provide the desired power and phase at the
transducer surface. The amplifier is interfaced to the elements of the cabled
transducer with an inductor/capacitor matching circuitry used to ensure
maximum power transfer.
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4 Evaluation of Phased Array in Ex Vivo and In Vivo Tissues
4.1 Introduction
Two sets of tissue experiments were performed to verify the intracavitary
array's capabilities. First, ex vivo bovine experiments were performed to
demonstrate the three dimensional range of the array. Second, in vivo rabbit thigh
experiments were used investigate the array's ability to coagulate large tissue
volumes. All experiments were performed with MRI guidance and thermometry.
The primary goal of this study was to demonstrate the feasibility of MRI-guided
ultrasound surgery using an intracavitary phased array.
4.2 Materials and Methods
4.2.1 MRI Experimental Setup
The ex vivo specimen or in vivo tissue was placed in the bore of a clinical
1.5 Tesla Signa MR imager (GE Medical Systems, Milwaukee, WI). Fresh beef
round meat was used in all ex vivo experiments to best approximate muscle
tissue. For all in vivo experiments, ultrasound ablation was performed in thigh
muscle of male New Zealand white rabbits. The animals were anesthetized with a
mixture of ketamine (48 mg/kg/hr, Fort Dodge Laboratories, Fort Dodge, IA) and
xylazine (12 mg/kg/hr, Fermenta Animal Health Co., Kansas City, MO) given as an
intra-muscular bolus every hour. The animal's body temperature was constantly
monitored with a copper-constantin rectal thermocouple (constructed in-house).
The rabbits were provided housing, food, and veterinary care according to NIH
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(NIH 1985) and Harvard Medical School guidelines. Ultrasound ablation was
performed in both rabbit thighs. To provide an optimal surface for acoustic
coupling, the hair from the thighs was removed with an electric shaver and hair
removing lotion (Nair, Carter Products, NY, NY).
GE 1.T Sig MRI Scemer
-Specimen
di64-channel
saa Ampliflier
Surface Coil System
50cl
Matching
Plasc Membrane
Degassed Wuar Applicaor Motor &
Encoder
Figure 4-1. Diagram of experimental setup. The intracavitary array was placed in
a degassed water bath, and the specimen, phantom or rabbit thigh, was placed
directly above the transducer. The MRI surface coil was positioned near the
lesion plane to improve image quality.
4.2.2 MRI Imaging Techniques
Through the course of the MRI experiments, three basic MR pulse
sequences were used: one sequence to locate the array in relation to the
specimen, a temperature sensitive sequence to locate the focus and monitor
temperature during ablation, and a third sequence to identify lesions in situ.
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Prior to sonications, fast spin-echo(FSE) T1-weighted images (TE/TR =
14/500ms, FOV = 20 cm, thickness, echo train length = 4, thickness = 3 mm,
matrix size = 256x128, NEX = 2, bandwidth = 16 kHz) were used to position the
array with respect to the specimen.
Once the array was properly positioned, temperature images were acquired
during a non-destructive low power sonication (25 electrical watts, 20 seconds) to
locate the array focus. These temperature images were obtained using the proton
chemical shift technique (proton resonant frequency shift constant = 0.00909
ppm/C; slice thickness = 3 mm, FOV = 16 cm, image acquisition time = 6.0 s,
TE/TR = 22.1/45.3 ms, NEX = 1, flip angle = 30*, echo train length = 1,
bandwidth = 3.13 kHz). Temperature images were also acquired during the
sonication and cooling times. For 20-second sonications, 9 temperature images
were obtained over a 60-second period, 3 during the sonication and 6 during the
cooling time. For the 30-second sonications, temperature images were also
obtained over a 60-second period, but 5 images were acquired during sonication
and 4 during cooling.
FSE T2-weighted images (TE/TR = 75/2000ms, echo train length = 8,
FOV = 16 cm, thickness = 3 mm, matrix size = 256x256, NEX = 2,
bandwidth = 16kHz) were used to identify the focused ultrasound lesions and
measure their sizes. Fresh Lesions appear as bright regions in a T2-weighted
MRI image, while older lesions appear as dark regions surrounded by a bright
ring. Edema can also be detected in the T2-weighted images; it appears as a
bright diffuse region and usually surrounds the ultrasound-induced lesion.
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4.2.3 Ultrasound Protocols
4.2.3.1 Ex Vivo experiments
Ex vivo bovine phantom experiments were performed to demonstrate the
phased array applicator's ability to electrically and mechanically move its focus
over a large volume. To demonstrate the axial range of the phased array, the
focus was electrically moved (by phasing the elements) in 5 mm increments along
the long axis of the array at a radial depth of 4 cm. All sonications were done at
low power, 25 electrical watts, for 20 seconds. Temperature images were
acquired during each sonication to verify the position of the focus. Then, the
arrays' ability to create a larger focus in a single sonication was evaluated. Larger
foci were created by rapidly switching between three closely spaced focal patterns
during a single 30-second sonication. The focal patterns, each a 4 cm-deep
focus, were spaced axially at 3 mm increments and scanned at 18 Hz. The large
foci generated by the 30-watt sonications were visualized with temperature
images. Finally, the transverse range of the phased array was verified by
generating 4 cm-deep scanned foci at different motor positions. The transducer
was rotated in increments of 150 and low power sonications, 30 watts, were
performed for 20 seconds at each position. Again, temperature images were used
to visualize the foci.
4.2.3.2 In vivo Experiments
In three rabbit thighs, a series of high power 30-second sonications, 130-160
watts each, were used to create large continuous lesions. These lesions were
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generated by 8-24 3 cm-deep foci. The constant depth foci were spaced
electrically by phasing and mechanically by rotation such that lesions larger than 6
cm3 could be produced. The focus was electrically moved in increments of 3 mm
in the axial direction, and the transducer was rotated in increments of 100. The
sonications were separated by at least one minute of cooling time to minimize
near-field tissue damage. Following the ablation experiments, the animal was
sacrificed and the rabbit thighs were dissected. The ultrasound lesion size was
quantified from the gross histology.
4.3 Results
4.3.1 Ex Vivo Experiments
Figure 4-2 is a radial-transverse (RT-plane) T1-weighted MRI image
showing the experimental setup. Both the array and the bovine specimen are
clearly visible in this image. The two perpendicular lines show the intersection of
the other two planes, the axial-transverse (AT) and axial-radial (AR) planes, with
the RT image plane. This coordinate system will be used in the subsequent
discussions of MRI images.
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Figure 4-2. TI-weighted radial-transverse (RT) plane image of the bovine
phantom setup. The two perpendicular lines show the axial-radial (AR) and axial-
transverse (AT) imaging planes.
Figure 4-3 shows the axial range of the transducer. To demonstrate this
range, the focus was electrically moved along the long axis of the transducer at a
constant radial depth of 4 cm. Figure 4-3a to Figure 4-3f, AT-plane temperature
images taken 4 cm from the transducer face, show the focus at -2 cm, -1.5 cm, -
1cm, 0 cm, 1cm, and 1.5cm, respectively. Figure 4-3g shows all of these foci
superimposed in the same AT-plane image. This image demonstrates that the
phased array can cover a 5.5 cm length along its axial dimension. Note that the
intensities of the -1 cm, -1.5 cm, and the -2 cm foci are higher than the others.
This is due to the array being slightly tilted in the AR-plane. In a series of similar
images not shown, the array's focusing ability in the depth dimension was verified
to be 3 cm, 2 to 5 cm from the transducer face.
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Figure 4-3. A T-plane temperature images showing the phasing abilities of the
array. (a)-(f) show the focus as it is moved along the axis of the array. (g) shows
all the foci superimposed in one image. The array has a range of 5.5 cm in the
axial direction.
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Figure 4-4 shows the AT-plane, AR-plane, and RT-plane temperature
images of an electrically switched focus. This focus was generated by switching
between 3 closely spaced 4-cm deep foci (-3 mm, 0 mm, 3 mm along the axis of
the transducer). Note that the scanned focus (Figure 4-4) is almost 3 times larger
than the conventional foci (Figure 4-3) in the AT-plane.
(a) (b)
(c)
Figure 4-4. A T-plane (a), AR-plane (b), and RT-plane (c) temperature images of a
4 cm-deep focus generated by switching. Arrows show the focus.
Figure 4-5 shows the transverse range of the transducer. To demonstrate this
range, a 4cm-deep focus was mechanically rotated in the RT image plane. Figure
4-5a to Figure 4-5e, RT-plane temperature images, show the 4cm-deep focus as
the transducer is rotated in increments of 150. Figure 4-5f depicts all of these foci
superimposed in the same RT-plane image. A transverse length of 6 cm can be
covered by the applicator via transducer rotation.
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Figure 4-5. RT-plane temperature images showing the transverse focusing range
of the array as it is mechanically rotated (arrows show focus). (a)-(f) show the
focus at different rotation angles. (g) shows all the foci superimposed in one
image. The array has a range of 6 cm in the transverse direction.
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4.3.2 In Vivo Experiments
MRI temperature images were used to monitor heating during the high
power sonications. These images helped to guide sonication spacing. Figure 4-6
shows AR-plane temperature images acquired during and after a 130-watt half-
minute sonication. Figure 4-6a shows the whole image plane 5 seconds after the
end of sonication (this temperature image can be registered with the T2-weighted
image shown in Figure 4-9). Figure 4-6b shows the temperature time course
during the 30-second sonication and during 25 seconds of the cooling time.
Temperature images acquired during the 30 seconds of sonication were noisy, but
still useful in localizing the focus in the tissue. Figure 4-7 shows a plot of the
average temperature rise across a 36 mm vertical distance (white line on Figure
4-6a) at the end of sonication. The peak temperature rise of 30*C occurs at the
focus. This plot did show negative temperature changes at some points
(approximately -20C maximum). This is within the error of the MR thermometry
technique, so the temperature rise was set to 00 C at these points. A plot of the
average temperature rise versus time at the focus can be seen in Figure 4-8. The
temperature at the focus increases during sonication, and decays immediately
after the sonication. The resulting lesion from this single sonication can be seen
in Figure 4-9 (indicated by the arrow). The shape and size of the lesion correlates
well with the temperature images acquired during the sonication.
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Figure 4-6. AR-plane temperature images acquired during a high power sonication
(130 watts, 30 seconds). (a) shows the whole temperature image at 35 second,
just after the sonication. (b) shows the temperature time course in the region
surrounding the focus. Note that the images acquired during sonication are noiser
than the others.
65
Temperature Rise Through Focus at Peak
19.8
2 16.5
13.2 .
E
9.9-
6.6 -
3.3 -
0.0
-18.8 -15.0 -11.3 -7.5 -3.8 0.0 3.8 7.5 11.3 15.0 18.8
Disance (mm)
Figure 4-7. Temperature profile along the 36 mm vertical distance shown in Figure
4-6a at the end of sonication. Negative temperature changes have been set to
zero.
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Figure 4-8. Temperature rise at the focus during sonication and during
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Figure 4-9. T2-weighted image after sonication and cooling. The arrow indicates
the lesion created by sonication shown in Figure 4-6.
Three large-volume lesions were created in vivo in rabbit thigh muscle.
Table 4-1 shows the sonication parameters and the resulting lesion size for each
treatment. Lesion size is noted in radial x axial x transverse dimensions. Side
effects of each treatment are also listed in the table. Treatment 1 produced the
largest lesion, but had the most severe side effects: edema and skin burn. In this
treatment, almost every position was sonicated twice. The smallest lesion was
created in treatment 2. This treatment consisted of 8 unique 130-watt sonications
regularly spaced in the target volume. Treatment 2 had no distinguishable side
effects. Treatment 3 consisted of 12 150-watt sonications regular spaced in the
target volume. In contrast to the other treatments, each sonication was initiated
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immediately after the one minute cooling time. The complete treatment was
conducted in less than 20 minutes. Mild edema was noted at the completion of
this treatment.
Table 4-1. Outcomes of the three ultrasound in vivo rabbit thigh treatments. The
soncations parameters, lesion size, and side effects of each treatment is listed in
the table.
Treatment Sonications Lesion Size Side Effects
(depth x length x width)
1 24 sonications 4 cm x 3 cm x 3 cm Edema, skin
120-150 watts burn
30 seconds
2 8 sonications 1.5 cm x 2 cm x 2 cm None
130 watts
30 seconds
3 12 sonications 3 cm x 2.5 cm x 2 cm Mild Edema
150 watts
30 seconds
Figure 4-11 shows AT and AR-plane T2-weighted MRI images of treatment
2 after eight half minute 130-watt sonications. Note that there is no evidence of
edema in the post sonication image. The ultrasound-induced lesion is highlighted
with the arrows. The lesion measures 1.5 cm x 2 cm in the AT plane and 2 cm x
1.5 cm in this AR image plane. The right lesion boundary in the AT image should
not be confused with the neighboring muscle layer, which also has a bright
intensity in the image. Figure 4-10 shows the gross histology of the lesion
resulting from treatment 2. The MRI-measured lesion size matched the lesion
dimensions determined from the histology.
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Figure 4-10. Gross histology of treatment 2. The lesion measures 1.5 cm X 2 cm
X 2 cm.
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(a)
(b)
Figure 4-11. T2-weighted images in the A T-plane (a) and in the AR-plane (b) after
8 sonications (130 watts, 30 seconds). The arrows indicate the ultrasound-
induced lesion boundary.
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4.4 Discussion
4.4.1 Ex vivo Bovine Phantom Experiments
The ex vivo studies clearly demonstrated the range of the intracavitary
phased array. The results indicate that foci can be created in a volume 5.5 cm x 6
cm x 3 cm (axial x transverse x radial). These dimensions represent an
operational maximum and not an absolute maximum volume. Only the center 45
elements of the phased array were powered in the ex vivo experiments. If all
elements were powered, the 5.5 cm dimension could be extended to at least 6.5
cm. The motor could have been rotated an additional 150 in both directions
further increasing the 6 cm transverse range of the applicator. Deeper foci were
not created because the phantom extended only 5 cm from the transducer
surface. Although a larger volume can be ablated, the operational maximum
volume is sufficient to cover the whole human prostate.
The bovine studies were also helpful in treatment planning. The MRI
images showed that each sonication created a focus roughly 7 mm x 3 mm x 1.5
cm in size. These dimensions were used in the spacing of the high power
sonications in the in vivo experiments.
4.4.2 In vivo Rabbit Thigh Experiments
The in vivo experiments showed that large tissue volumes could be ablated
with a linear intracavitary phased array. Furthermore, the number of sonications
used to create these large lesions shows potential for a reasonably fast whole
prostate ablation treatment. The lesion created in the third treatment represents a
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volume half that of the human prostate. Since that treatment was performed in 20
minutes, a volume the size of a human prostate could be ablated in 40 minutes.
This treatment time represents a maximum. The duration can be reduced if
additional experiments are performed to determine the optimal sonication protocol.
Scanned foci, more sparsely spaced foci, or higher power foci may be used to
reduce treatment times.
In this study, MRI thermometry helped determine the spacing between
successive sonications. However, the temperature images acquired during
sonications were noisy. Image corruption during sonication was high due to
reflected power in the transducer. For sonications greater than 130 watts, at least
4 watts were reflected. The reflected RF power distorts the RF signals picked up
the MR surface coil. If reflected power can be controlled, either by better
transducer matching or by deactivating highly reflective elements, better
temperature images can be acquired. Improved MR thermometry would then
allow for accurate thermal dose maps, and dosage calculations can be directly
used to position the multiple sonications involved in one treatment (Chung et al.
1999). A MRI temperature feedback system can be developed which would not
only optimize the sonication protocol but also speed up treatment.
The major side effects of large volume ablation were edema and skin burn
caused by near field heating. These are serious concerns since these effects
would translate into rectal wall heating in prostate treatments. Edema and skin
burn were prominent in the first treatment. The cause of near field heating in this
treatment was probably due to too many sonications within a targeted volume with
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too short interval between the sonications. The first treatment used twice the
number of sonications as the third treatment, yet the sonications covered the
same volume. The third treatment had no skin burn and only mild edema. Further
experiments need to be performed to determine the best sonication protocol for
eliminating near field heating. These side effects could also be caused by high
powers. In the treatments that had edema, powers greater than 130 watts were
used. Treatment 2, which had no side effects, was performed with 120-watt
sonications. In addition, short cooling times could be the cause of near field
heating. These times could be extended to minimize thermal dose accumulation in
the near field. As in the ex vivo experiments, only 45 elements of the array were
powered during sonications. Powering all the elements of the phased array may
also reduce the amount of heat deposited in the near field.
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5 Conclusions and Recommendations for Future Work
This study has demonstrated the feasibility of whole prostate ablation with
a linear intracavitary phased array. The constructed array has demonstrated that
sufficient powers for large volume ablation could be reliably achieved with an
intracavitary linear phased array. The thermal prostatectomy technique could
provide a definitive, safe, minimally invasive treatment for BPH, T1 and T2
prostate cancers.
However, steps remain before this technique can be tested in humans.
Developing the proper sonication protocols is perhaps the most important step.
Further animal studies will help determine the appropriate spacing between
lesions, and the sonication powers and times. The optimal solution to this,
however, can be achieved by calculating thermal dose from MRI temperature
images during sonication. If the MR image noise during sonication can be
reduced, then thermal dose can be used to accurately predict the lesion size.
Then based on the lesion size estimation, the parameters for the subsequent
sonications can be appropriately adjusted. A complete MRI temperature
feedback system could be developed where the only user input is to determine
the volume to be coagulated.
While the treatment planning is being developed, the array geometry could be
modified to reduce the near field heating problems. One way to do this is
reduce element widths down to X/2, this geometry would give us maximum
flexibility in focusing while reducing lobe structure. Another geometry that can be
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studied is to introduce a curvature to the linear array to add a geometric gain.
This geometry might minimize the heat deposit in the near field. These
geometries can be studied with acoustic field simulations prior to array
fabrication.
Although advancements were made in fabrication, some work in
improving the construction and performance of the array remains. Waterproofing
still remains an issue, initial experiments with this array were unsuccessful due to
leaking. In addition although the ground plane was robust, this too can be
improved to obtain some gain in acoustic efficiency. But more importantly, a
better ground plane might reduce the noise generated by reflected powers.
Some new ideas for ground plane improvement include: replatting the electrode
after dicing and filling, using silver impregnated silicone to connect the ground
electrodes of all the elements, constructing a piezocomposite array that does not
need to be diced.
This technique must be tested in animal prostate models. Creating large
lesions in muscle shows feasibility, but some issues remain when attempting to
ablate large prostate volumes. First, the level of rectal wall heating with this
array needs to investigated. Second, the ability to ablate prostate tissue
immediately adjacent to the rectal wall needs to be verified. If these organ-
specific issues along with the aforementioned technical issues can be worked
out, then whole prostate ablation with intracavitary ultrasound can become a key
treatment option for both BPH and prostate cancer patients.
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